Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

Octoplus Begins Doubling of Facilities

  • OctoPlus has begun construction work to more than double its facilities. “The expansion is necessary to support clinical development for the company’s own products and to facilitate the growing demand for the company’s services,” says Joost Holthuis, CEO.

    The company’s existing facilities comprise offices, laboratories, and a GMP manufacturing plant that produces clinical-scale GMP batches for the development of OctoPlus’ own products and for its formulation development customers.

    The new facilities will bring the current 2,800-sq-m building to a combined total of 6,300-sq-m. The company plans to move into the building toward the end of 2007.

    The building will be constructed and owned by Fortress Participations, which will lease it to OctoPlus, which, in turn, will invest in research equipment and GMP production equipment to operate the facilities. It will be located adjacent to OctoPlus’ headquarters in the Bio Science Park in Leiden, The Netherlands.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »